MedTrace Logo

Micro-Clinic Obesity and Metabolic Risk Prevention Program

NCT01651065 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 494

Last updated 2024-02-07

No results posted yet for this study

Summary

The purpose of this randomized trial is to study the efficacy of a novel social propagation intervention which integrates social network induction with health education for weight and metabolic control among patients with type 2 diabetes, BMI of 25-30+, and cardiovascular disease. The intervention takes place in the form of a community health program, where participants who enroll in this program will be asked if they would like to take part in the study to evaluate its efficacy. Thus, the investigators will study the efficacy of social networks in propagating changes in lifestyle factors for diabetes and chronic disease management

Conditions

Interventions

BEHAVIORAL

Microclinic Diabetes Education Program

The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts. The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors.

BEHAVIORAL

Control

Sponsors & Collaborators

  • Bell County Department of Health, Kentucky

    collaborator UNKNOWN

  • Microclinic International

    lead OTHER

Principal Investigators

  • Daniel E Zoughbie, D.Phil. · Microclinic International

  • Eric L Ding, Sc.D. · New England Complex Systems Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01651065 on ClinicalTrials.gov